Summary
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
PHILADELPHIA , June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera. Shareholders of PFIZER may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bm.net or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015 or visit: Click Here Berger Montague's investigation is focused on whether Pfizer's Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company's marketing and sale of Depo-Provera, an injectable used for contraception or to treat endometriosis, as well as other indications.
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.
Buy, Sell, Or Hold PFE Stock At $23?
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.
PANTERA FPO Dividends
 PFE 3 weeks ago Announced | Quarterly | $0.43 Per Share |
| PFE 4 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 6 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 10 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 9 May 2024 Paid | Quarterly | $0.42 Per Share |
PANTERA FPO Earnings
| 28 Jul 2025 (55 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
| 28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
| 29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
| PFE 3 weeks ago Announced | Quarterly | $0.43 Per Share |
| PFE 4 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 6 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 10 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 9 May 2024 Paid | Quarterly | $0.42 Per Share |
| 28 Jul 2025 (55 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
| 28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
| 29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
PANTERA FPO (PFE) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has PANTERA FPO ever had a stock split?
PANTERA FPO Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Dr. Albert Bourla D.V.M., Ph.D. CEO | CXA Exchange | US7170811035 ISIN |
| US Country | 81,000 Employees | 24 Jan 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Overview
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.
Products and Services
- Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
- Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
- Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
- Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
- Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
- Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
- Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
- Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.
Contact Information
